Crimean-Congo hemorrhagic fever: epidemiological trends and controversies in treatment
1 Department for Interventions in Health-Care Facilities, Hellenic Center for Disease Control and Prevention, 3-5 Agrafon Street, Athens, 15123 Greece
2 Department of Microbiology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
Citation and License
BMC Medicine 2011, 9:131 doi:10.1186/1741-7015-9-131Published: 8 December 2011
Crimean-Congo hemorrhagic fever (CCHF) virus has the widest geographic range of all tick-borne viruses and is endemic in more than 30 countries in Eurasia and Africa. Over the past decade, new foci have emerged or re-emerged in the Balkans and neighboring areas. Here we discuss the factors influencing CCHF incidence and focus on the main issue of the use of ribavirin for treating this infection. Given the dynamics of CCHF emergence in the past decade, development of new anti-viral drugs and a vaccine is urgently needed to treat and prevent this acute, life-threatening disease.